Udg Healthcare (UDG) Given Buy Rating at Peel Hunt
UDG has been the topic of several other research reports. Liberum Capital reaffirmed a buy rating on shares of Udg Healthcare in a research report on Thursday, November 22nd. Numis Securities reaffirmed a hold rating and set a GBX 660 ($8.62) price objective on shares of Udg Healthcare in a research report on Tuesday, November 27th. Berenberg Bank reiterated a hold rating and set a GBX 750 ($9.80) target price on shares of Udg Healthcare in a research note on Tuesday, November 27th. Finally, Jefferies Financial Group lowered their target price on shares of Udg Healthcare from GBX 890 ($11.63) to GBX 765 ($10.00) and set a buy rating for the company in a research note on Friday, December 14th. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock currently has an average rating of Hold and an average price target of GBX 802.71 ($10.49).
Shares of Udg Healthcare stock opened at GBX 562 ($7.34) on Tuesday. The company has a market cap of $1.40 billion and a PE ratio of 374.67. Udg Healthcare has a 1-year low of GBX 548 ($7.16) and a 1-year high of GBX 950.50 ($12.42). The company has a debt-to-equity ratio of 27.53, a quick ratio of 1.80 and a current ratio of 2.02.
About Udg Healthcare
UDG Healthcare plc, together with its subsidiaries, provides advisory, communication, commercial, clinical, and packaging services in the Republic of Ireland, the United Kingdom, North America, and internationally. The company operates in two segments, Ashfield and Sharp. The Ashfield segment offers commercialization services for the pharmaceutical and healthcare industry in the areas of advisory, communications, and commercial and clinical services.
Featured Story: How to find the components of the quick ratio
Receive News & Ratings for Udg Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Udg Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.